IDEXX Laboratories, IncNasdaq: IDXX
Health Care · Health Care Equipment
$570.94
+3.23%
Vol: 32K
Research Digest
Monday, June 15, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21IDEXX promotes Mike Erickson to CEO; raises 2026 guidance after Q1 beatPositive▶
IDEXX promoted Michael Erickson to President and CEO effective May 12, 2026, with Jay Mazelsky becoming Executive Chair. Q1 2026 revenue of $1.14B (vs $1.11B consensus) grew 14% reported/11% organic; EPS $3.47 up 17%. Raised 2026 EPS guidance to $14.45-$14.90 and revenue to $4.68B-$4.76B. Announced 2026 Investor Day on Aug 13 and Stifel conference May 27. Integrated SDMA kidney markers into Catalyst chemistry profiles.
May 20IDEXX shares rose 3.2% to $545.79 after shareholders approved governance reforms and the company integrated its SDMA biomarker into Catalyst CLIPs, following a strong Q1 with 11% organic growth and raised 2026 EPS guidance.Positive▶
IDEXX Laboratories announced on May 15 that its SDMA biomarker is now integrated into the most common Catalyst chemistry profiles, expanding routine kidney screening across its veterinary diagnostics platform. The same day, shareholders approved governance and meeting reforms at the annual meeting. Shares rose 3.2% on May 18 to $545.79, continuing a strong run following Q1 2026 results that showed revenue of $1.141B (up 14%) and EPS of $3.47 (up 17%), prompting management to raise 2026 EPS guidance to $14.45-$14.90. CEO Mike Erickson will appear at the Stifel Jaws & Paws Conference on May 27, and IDEXX scheduled an Investor Day for August 13. Key risk: continued slower-growth concerns in certain segments and high valuation multiples leave the stock sensitive to any veterinary visit slowdown.
May 19IDEXX shares rose 3.2% to $545.79 on May 18 after raising 2026 guidance, but BofA cut PT to $660 on slower inVue installations.Mixed▶
IDEXX Q1 (May 5) revenue $1.141B (+14% reported, +11% organic) with EPS $3.47 (+17%). Raised FY26 outlook to $4.68B-$4.76B revenue and $14.45-$14.90 EPS, targeting 5,500 inVue Dx placements. On May 18 shares rose 3.2% to $545.79. Stifel Jaws & Paws conference May 27; Investor Day Aug 13. Wright reiterated Buy with PT raised to $805; BofA lowered PT to $660 from $790. Bear case: slower inVue installations and macro veterinary visit headwinds may cap multiple expansion.
May 18No significant overnight updatesNeutral▶
No material news in the last 48 hours. Earlier May developments included a Q1 beat (revenue $1.14B, EPS $3.47), raised full-year 2026 guidance ($14.45-$14.90 EPS), an announced fireside chat at the Stifel Jaws & Paws Conference on May 27, and a 2026 Investor Day scheduled for August 13.
May 15IDEXX announces 2026 Investor Day (Aug 13) and Stifel conference appearance May 27 after strong Q1 beatPositive▶
IDEXX Laboratories announced on May 14 that CEO Mike Erickson will participate in a fireside chat at the Stifel Jaws & Paws Conference on May 27, and that the company will host its 2026 Investor Day on August 13 at its Westbrook, Maine headquarters. The setup follows Q1 2026 revenue of $1,141M (+14% reported, +11% organic) and diluted EPS of $3.47 (+17% reported, +15% comparable), with CAG growth of 15% reported / 12% organic. Full-year guidance for revenue, EPS, and operating margin was raised. Consensus is Buy with average PT of $721.50 (35% implied upside). Risk: premium valuation; companion-animal visit growth remains the key swing factor.
May 14IDEXX names Mike Erickson CEO effective May 12 as Q1 EPS of $3.47 beats and 2026 guidance raises to $14.45-$14.90 EPS on $4.68-$4.76B revenueMixed▶
IDEXX promoted Michael (Mike) Erickson, PhD to President and CEO effective May 12, 2026, with prior CEO Jay Mazelsky transitioning to Executive Chair. Q1 2026 revenue rose 14% as reported (11% organic) to $1,141M with EPS of $3.47, beating consensus by $0.06 and driven by Companion Animal Group growth of 15%. The company raised 2026 full-year guidance to $14.45-$14.90 EPS and $4.68-$4.76B revenue. Despite the beat, shares fell 5.0% on May 11 and another 4.7% on May 12 to $533.92 on concerns over installation rates and macro headwinds. BofA Securities lowered its PT to $660 citing those concerns. The IDEXX Cancer Dx Panel expanded into the UK in April, broadening higher-value testing access. Risk: consumer-driven vet visit softness and instrument placement slowdown.
May 13IDEXX Laboratories' CEO succession became effective May 12, with Michael Erickson promoted to President and CEO as Jay Mazelsky transitions to Executive Chair.Positive▶
IDEXX Laboratories' previously announced CEO succession became effective on May 12, 2026, with Michael (Mike) Erickson, PhD, promoted to President and Chief Executive Officer, while Jonathan (Jay) Mazelsky transitions to Executive Chair of the Board. The leadership transition follows strong Q1 2026 results reported May 5, with revenue of $1.14 billion (up 14%) and EPS of $3.47 beating estimates by $0.06. The company raised full-year 2026 guidance to revenue of $4.68-$4.76 billion and EPS of $14.45-$14.90. Companion Animal Group growth was 15% reported, 12% organic. BofA Securities lowered its price target to $660 over concerns about installation rates and macroeconomic trends. Shares were at $559.06 as of May 11.
May 12IDEXX raises FY26 EPS guidance to $14.45-$14.90 after Q1 organic revenue grew 11% and Companion Animal Group up 15%Positive▶
IDEXX Q1 2026 revenue of $1,141M grew 14% reported / 11% organic; EPS of $3.47 up 17%. Companion Animal Group (CAG) led with 15% reported / 12% organic growth. Gross margin up 90bps on consumables strength. Management raised FY26 revenue outlook to $4.68B-$4.76B and EPS guidance to $14.45-$14.90 (up $0.13 at midpoint). April expansion of the IDEXX Cancer Dx Panel into the UK supports the diagnostics growth narrative. Shares trading near $559 as of May 11.
May 11IDEXX raises 2026 EPS outlook to $14.45-$14.90 after Q1 revenue grew 14% organically; CEO succession effective May 12Positive▶
IDEXX Laboratories reported strong Q1 2026 results with revenue of $1.141 billion, up 14% as reported and 11% organic, driven by Companion Animal Group growth of 15% as reported. EPS reached $3.47, up 17%. The company raised its 2026 EPS outlook to $14.45-$14.90 and revenue guidance by $42 million at midpoint, citing strong execution, higher diagnostic utilization, inVue Dx and Cancer Dx expansion, and international performance. IDEXX announced CEO succession with Michael Erickson, PhD becoming President and CEO effective May 12, 2026, while Jay Mazelsky moves to Executive Chair. The company also launched the ImageVue DR50 Plus Digital Imaging System. Net margin expanded to 24.6% from 22.8%. Results contrast sharply with Zoetis weakness, suggesting IDEXX is taking share.
May 8IDEXX beats Q1, raises 2026 guidance; CEO transition to Erickson announcedPositive▶
IDEXX Laboratories reported Q1 2026 revenue of $1,141M (+14% reported, +11% organic), with diluted EPS of $3.47 (+17% reported, +15% comparable). Strong Companion Animal Group growth of +15% reported (+12% organic). Company raised FY2026 EPS guidance to $14.45–$14.90 and projects revenue of $4.675–$4.760B with 8.6%–10.6% growth. CEO Jay Mazelsky transitioning to executive board chair, with Michael Erickson becoming CEO. Mazelsky staying through May 2027 retirement. Multiple analyst price target increases: Piper Sandler to $775 from $700, Morgan Stanley to $805 from $765. Average analyst rating is "Buy" with 12-month target of $721.67. Stock momentum strong on robust organic growth and leadership continuity plan.
May 7IDEXX Laboratories reports strong Q1 with 14% reported and 11% organic revenue growth; raises FY26 EPS guidance to $14.45-14.90Positive▶
IDEXX reported Q1 2026 revenue of $1.141B, up 14% as reported and 11% organic, with CAG growth 15% reported and 12% organic. Diluted EPS $3.47 up 17% as reported and 15% comparable basis. Company raised FY26 EPS guidance to $14.45-14.90 (+$0.13 vs prior midpoint) on strong results and operating margin expansion. Guided FY26 revenue $4.675-4.760B with 8.6-10.6% growth and 7.7-9.7% organic growth. CEO Jay Mazelsky winding down term; Michael Erickson takes helm with Mazelsky staying as executive board chair until May 2027. 9 analysts rate Buy with $721.67 PT (28.2% upside).
May 6IDEXX Laboratories beats and raises: Q1 revenue $1.141B (+14% reported, +11% organic) with EPS of $3.47Positive▶
IDEXX Laboratories delivered strong Q1 2026 beat with revenue of $1.141B (+14% reported, +11% organic) and EPS of $3.47 vs $3.41 forecast. Companion Animal Diagnostics surged 33% reported (28% organic) on 1,100 inVue Dx analyzer placements; gross margin expanded 90bps to 63.4%. FY26 guidance raised to EPS $14.45-$14.90 on revenue $4.675-4.760B; CEO moves to exec chair, Michael Erickson becomes CEO. BofA cut price target to $660 from $790 (Neutral).
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| IDXXIDEXX | $570.94 | +3.23% | +1.3% | 33.5x | 1.57 | $43.6B |
| ISRGINTUITIVE | $416.51 | -5.30% | -0.0% | 37.3x | 1.51 | $155.8B |
| ABTABBOTT | $88.21 | +0.50% | -0.2% | 14.5x | 0.65 | $152.9B |
| SYKSTRYKER | $310.30 | -1.02% | +0.1% | 18.8x | 0.81 | $120.2B |
| MDTMEDTRONIC | $80.25 | +2.69% | +1.1% | 12.9x | 0.63 | $100.3B |
| BSXBOSTON | $47.37 | -17.11% | +2.2% | 15.2x | 0.62 | $84.9B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.